Leerink analyst Joseph Schwartz initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Outperform rating and a price target of $13.00.

For an analyst ratings summary and ratings history on Larimar Therapeutics click here. For more ratings news on Larimar Therapeutics click here.

Shares of Larimar Therapeutics closed at $3.92 yesterday.